CONMED (CNMD) Aperçu de l'action
CONMED Corporation, une entreprise de technologie médicale, développe, fabrique et vend des dispositifs et des équipements pour les procédures chirurgicales. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 3/6 |
| Performances passées | 1/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
CNMD Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CONMED Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$36.80 |
| Plus haut sur 52 semaines | US$61.08 |
| Plus bas sur 52 semaines | US$33.21 |
| Bêta | 0.99 |
| Variation sur 1 mois | 5.78% |
| Variation sur 3 mois | -6.15% |
| Variation sur 1 an | -36.20% |
| Variation sur 3 ans | -70.64% |
| Variation sur 5 ans | -74.38% |
| Évolution depuis l'introduction en bourse | 1,740.00% |
Nouvelles et mises à jour récentes
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.
CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.Recent updates
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.CNMD: Execution Rebound And Margin Focus Will Support Future Upside
The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile
Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile
Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns
Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile
Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.
CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion
Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead
Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns
Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.Conmed Taking On More Pain In The Pursuit Of Future Gain
Dec 15CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns
Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value
CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value
CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well
Oct 06
CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
Sep 12CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals
Aug 08Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?
Jul 03CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
May 24CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market
May 17Is CONMED (NYSE:CNMD) Using Too Much Debt?
Mar 31Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
Feb 28CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
Feb 28CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08CONMED Corporation (NYSE:CNMD) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 20Is Now The Time To Look At Buying CONMED Corporation (NYSE:CNMD)?
Jan 01CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20
Dec 13Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Nov 25CONMED's (NYSE:CNMD) Earnings Are Weaker Than They Seem
Nov 07Earnings Beat: CONMED Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 02Should You Investigate CONMED Corporation (NYSE:CNMD) At US$71.92?
Oct 01Rendement pour les actionnaires
| CNMD | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -4.0% | -4.2% | 0.8% |
| 1Y | -36.2% | -18.5% | 27.8% |
Rendement vs Industrie: CNMD a sous-performé le secteur US Medical Equipment qui a rapporté -18.5 % au cours de l'année écoulée.
Rendement vs marché: CNMD a sous-performé le marché US qui a rapporté 27.8 % au cours de l'année écoulée.
Volatilité des prix
| CNMD volatility | |
|---|---|
| CNMD Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: CNMD n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CNMD ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1970 | 3,900 | Pat Beyer | www.conmed.com |
CONMED Corporation, une société de technologie médicale, développe, fabrique et vend des appareils et du matériel pour les procédures chirurgicales. La société propose des produits de chirurgie orthopédique, notamment BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, et Agro Knotless Suture Anchors, qui offrent des solutions cliniques aux chirurgiens orthopédiques pour l'augmentation et la réparation des lésions des tissus mous, ainsi que des produits complémentaires, notamment des instruments de résection motorisés, des systèmes de gestion des fluides et de visualisation et des produits connexes à usage unique qui permettent aux chirurgiens d'effectuer des interventions mini-invasives en médecine du sport. Elle fournit également des systèmes d'outils électriques à batterie, autoclavables, pour petits et grands os, destinés à la chirurgie orthopédique, arthroscopique, orale/maxillofaciale, podiatrique, rachidienne et cardiothoracique, sous la marque Hall surgical.
CONMED Corporation Résumé des fondamentaux
| CNMD statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.11b |
| Bénéfices(TTM) | US$54.85m |
| Recettes(TTM) | US$1.37b |
Le site CNMD est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CNMD compte de résultat (TTM) | |
|---|---|
| Recettes | US$1.37b |
| Coût des recettes | US$624.24m |
| Marge brute | US$746.27m |
| Autres dépenses | US$691.42m |
| Les revenus | US$54.85m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 1.82 |
| Marge brute | 54.45% |
| Marge bénéficiaire nette | 4.00% |
| Ratio dettes/capitaux propres | 80.7% |
Quelles ont été les performances à long terme de CNMD?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/03 09:09 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CONMED Corporation est couverte par 16 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Travis Steed | Barclays |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |